Independent register of U.S. FDA drug recalls · updated Oct 11, 2026
RxRecalls Get alerts

Class II drug recalls - moderate risk

Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.

14,535 recalls, newest first.

Class II · Moderate risk

Clear Eyes

Failed Impurities Specification: Out-of-specification (OOS) stability test result was obtained for unspecified impurity.

Terminated Impurity / degradation Teva Pharmaceuticals USA Inc NDC 67172-504-01 D-0469-2023
Class II · Moderate risk

NaturalCare

CGMP Deviations: Raw material recalled by repackager, due to discoloration.

Ongoing Failed specification Nutraceutical Corporation D-0440-2023
Class II · Moderate risk

NaturalCare bioAllers

CGMP Deviations: Raw material recalled by repackager, due to discoloration.

Ongoing Failed specification Nutraceutical Corporation D-0439-2023
Class II · Moderate risk

NatraBio

CGMP Deviations: Raw material recalled by repackager, due to discoloration.

Ongoing Failed specification Nutraceutical Corporation D-0438-2023
Class II · Moderate risk

NaturalCare bioAllers

CGMP Deviations: Raw material recalled by repackager, due to discoloration.

Ongoing Failed specification Nutraceutical Corporation D-0437-2023
Class II · Moderate risk

Carbidopa and Levodopa Tablets

Packaging defect: observed packaging defect, blister packaging inadequately sealed.

Terminated Packaging defect The Harvard Drug Group NDC 0904-7257-61 D-0432-2023
Class II · Moderate risk

Testosterone Cypionate Injection

cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.

Terminated cGMP deviation Azurity Pharmaceuticals, Inc. NDC 52536-625-10 D-0489-2023

Recalls by year